دورية أكاديمية

Evidence of aberrant anti-epstein-barr virus antibody response, though no viral reactivation, in people with post-stroke fatigue

التفاصيل البيبلوغرافية
العنوان: Evidence of aberrant anti-epstein-barr virus antibody response, though no viral reactivation, in people with post-stroke fatigue
المؤلفون: Isobel C. Mouat, Li Zhu, Alperen Aslan, Barry W. McColl, Stuart M. Allan, Craig J. Smith, Marion S. Buckwalter, Laura McCulloch
المصدر: Journal of Inflammation, Vol 21, Iss 1, Pp 1-10 (2024)
بيانات النشر: BMC, 2024.
سنة النشر: 2024
المجموعة: LCC:Therapeutics. Pharmacology
مصطلحات موضوعية: Ischaemic stroke, Fatigue, Epstein-Barr virus, Therapeutics. Pharmacology, RM1-950
الوصف: Abstract Background Fatigue is a common complication of stroke that has a significant impact on quality of life. The biological mechanisms that underly post-stroke fatigue are currently unclear, however, reactivation of latent viruses and their impact on systemic immune function have been increasingly reported in other conditions where fatigue is a predominant symptom. Epstein-Barr virus (EBV) in particular has been associated with fatigue, including in long-COVID and myalgic encephalomyelitis/chronic fatigue syndrome, but has not yet been explored within the context of stroke. Aims We performed an exploratory analysis to determine if there is evidence of a relationship between EBV reactivation and post-stroke fatigue. Methods In a chronic ischemic stroke cohort (> 5 months post-stroke), we assayed circulating EBV by qPCR and measured the titres of anti-EBV antibodies by ELISA in patients with high fatigue (FACIT-F 41). Statistical analysis between two-groups were performed by t-test when normally distributed according to the Shapiro-Wilk test, by Mann-Whitney test when the data was not normally distributed, and by Fisher’s exact test for categorical data. Results We observed a similar incidence of viral reactivation between people with low versus high levels of post-stroke fatigue (5 of 22 participants (24%) versus 6 of 22 participants (27%)). Although the amount of circulating EBV was similar, we observed an altered circulating anti-EBV antibody profile in participants with high fatigue, with reduced IgM against the Viral Capsid Antigen (2.244 ± 0.926 vs. 3.334 ± 2.68; P = 0.031). Total IgM levels were not different between groups indicating this effect was specific to anti-EBV antibodies (3.23 × 105 ± 4.44 × 104 high fatigue versus 4.60 × 105 ± 9.28 × 104 low fatigue; P = 0.288). Conclusions These data indicate that EBV is not more prone to reactivation during chronic stroke recovery in those with post-stroke fatigue. However, the dysregulated antibody response to EBV may be suggestive of viral reactivation at an earlier stage after stroke.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1476-9255
Relation: https://doaj.org/toc/1476-9255
DOI: 10.1186/s12950-024-00402-0
URL الوصول: https://doaj.org/article/00035330a4e44ca69fd858152c523075
رقم الأكسشن: edsdoj.00035330a4e44ca69fd858152c523075
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:14769255
DOI:10.1186/s12950-024-00402-0